BIVACOR
BiVACOR is a privately held company founded in 2008. Their staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, they have established a strong collaborative network that extends both nationally and internationally. Their world headquarters is located in Houston, Texas, USA, and their international office is in Brisbane, Australia.
BIVACOR
Industry:
Life Science Manufacturing Medical Device
Founded:
2008-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.bivacor.com
Total Employee:
1+
Status:
Active
Total Funding:
22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Font Awesome Apache Google Apps For Business
Similar Organizations
Current Employees Featured
Daniel Timms Founder, CEO and CTO @ BiVACOR
Founder, CEO and CTO
2013-04-01
John Fraser Chief Medical Officer and Co-Founder @ BiVACOR
Chief Medical Officer and Co-Founder
2008-10-01
William E Cohn Chief Medical Officer & Board of Directors @ BiVACOR
Chief Medical Officer & Board of Directors
2012-01-01
Founder
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series B - BiVACOR
National Institutes of Health
National Institutes of Health investment in Grant - BiVACOR
OneVentures
OneVentures investment in Series B - BiVACOR
OneVentures
OneVentures investment in Venture Round - BiVACOR
Official Site Inspections
http://www.bivacor.com
- Host name: 970007.cloudwaysapps.com
- IP address: 159.203.44.142
- Location: Toronto Canada
- Latitude: 43.6547
- Longitude: -79.3623
- Timezone: America/Toronto
- Postal: M5A
More informations about "BiVACOR"
BiVACOR - Crunchbase Company Profile & Funding
Organization. BiVACOR . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. BiVACOR designs …See details»
BiVACOR
BiVACOR® is a privately held company founded in 2008. Our staff includes world-class engineers, medical specialists, and business executives, who are diligently working to …See details»
Approval for First-in-Human E arly Feasibility Study US FDA
BiVACOR was founded in 2008 by a team of internationally renowned biomedical engineers and cardiac surgeons, including Founder and Chief Technical Officer Daniel Timms, Ph.D., and …See details»
BiVACOR 2025 Company Profile | PitchBook
BiVACOR General Information Description. Developer of an artificial heart-pumping device designed to take over the complete function of a patient's …See details»
BiVACOR Company Profile | Management and Employees List
BiVACOR® is a preclinical stage medical device company developing the BiVACOR Total Artificial Heart (TAH), the first long-term therapy for patients with severe heart failure. ...See details»
BiVACOR - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Venture Round - BiVACOR . …See details»
BiVACOR - Overview, News & Similar companies | ZoomInfo.com
The Texas Heart Institute Implants BiVACOR® Total Artificial Heart HOUSTON--(BUSINESS WIRE)--The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device …See details»
BiVACOR Overview | SignalHire Company Profile
The position of the Founder & CEO is occupied by Daniel Timms. Its headquarters is located at Houston, Texas, USA. The number of employees ranges from 25 to 100. The annual revenue …See details»
BiVACOR - Updates, News, Events, Signals & Triggers - Crunchbase
BiVACOR may be growing as the company has developed a world-first artificial heart, which indicates a significant achievement in product innovation within the medical device industry. …See details»
BiVACOR secures $13m for total artificial heart …
Feb 21, 2024 BiVACOR is gearing up to commence a first-in-human feasibility study for its total artificial heart. The device is designed for long-term treatment of patients with severe biventricular heart failure. The study (NCT06174103) will …See details»
BiVACOR Total Artificial Heart: Australia’s first recipient of ...
Mar 12, 2025 Almost two decades after his father died from heart failure, Daniel Timms has helped to transform treatment for patients across the globe. His invention, the BiVACOR Total …See details»
BiVACOR® Receives $18 Million in Funding to Move the Total …
BiVACOR is developing the BiVACOR Total Artificial Heart (TAH), designed as the first long-term therapy dedicated for patients with severe biventricular heart failure. The BiVACOR device is …See details»
‘Incredibly rewarding’: FDA expands total artificial heart study after ...
Dec 18, 2024 BiVacor, the California-based medical device company known for its total artificial heart (TAH) technology, has completed the initial phase of an early feasibility study (EFS) first …See details»
OneVentures-backed artificial heart start-up BiVACOR rattles the …
Mar 16, 2025 The BiVACOR capital raise comes as Infensa Bioscience, another local medical company, prepares to seek $23 million from investors. Infensa is developing a drug that uses …See details»
Biomedical Translation Fund invests in further development of …
May 16, 2018 OneVentures, a venture capital firm focused on investment in high growth, transformative technology and healthcare companies, is pleased to announce that its …See details»
News – BiVACOR, Inc.
Jul 25, 2024 The Texas Heart Institute (THI), a globally renowned cardiovascular health center, and BiVACOR , a leading clinical-stage medical device company, are pleased to provide an …See details»
Australian government offers grant support to artificial heart …
Feb 20, 2024 BiVACOR, a clinical-stage medical device company, has announced that US$13 million has been awarded from the Australian government’s Medical Research Future Fund …See details»
BiVACOR: $13 Million Grant Received From Australian Government
Feb 21, 2024 BiVACOR - a clinical-stage medical device company - announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) …See details»
BiVACOR heart device moves to phase 2 of FDA trial | khou.com
Feb 21, 2025 The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients. We spoke with the first human recipient of a BiVACOR heart …See details»
RESPONSIBILITIES - bivacor.com
The QE III will also work with BiVACOR senior management to implement and supports maintenance of quality management system in accordance with ISO 13485 and 21 CFR 820, …See details»